- Report
- August 2025
- 199 Pages
Global
From €3130EUR$3,545USD£2,713GBP
€3478EUR$3,939USD£3,015GBP
- Report
- April 2025
- 175 Pages
Global
From €3965EUR$4,490USD£3,436GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1766EUR$2,000USD£1,531GBP
- Report
- May 2025
- 149 Pages
Global
From €2648EUR$2,999USD£2,295GBP
- Report
- May 2025
- 86 Pages
Global
From €3500EUR$4,246USD£3,140GBP
- Report
- August 2025
- 196 Pages
Global
From €5165EUR$5,850USD£4,477GBP
- Report
- July 2025
- 350 Pages
Global
From €4370EUR$4,949USD£3,788GBP
- Report
- January 2025
- 99 Pages
Global
From €3086EUR$3,495USD£2,675GBP
- Report
- August 2025
- 190 Pages
Global
From €3130EUR$3,545USD£2,713GBP
€3478EUR$3,939USD£3,015GBP
- Report
- August 2025
- 192 Pages
Global
From €3130EUR$3,545USD£2,713GBP
€3478EUR$3,939USD£3,015GBP
- Report
- April 2025
- 200 Pages
Global
From €3965EUR$4,490USD£3,436GBP
- Report
- March 2025
- 200 Pages
Global
From €3965EUR$4,490USD£3,436GBP
- Report
- March 2025
- 219 Pages
Global
From €2207EUR$2,500USD£1,913GBP
- Report
- March 2022
- 300 Pages
Global
From €4415EUR$5,000USD£3,827GBP
- Report
- August 2024
- 146 Pages
Global
From €2648EUR$2,999USD£2,295GBP
- Report
- September 2023
- 90 Pages
Egypt
From €3090EUR$3,500USD£2,679GBP
- Report
- August 2023
- 73 Pages
Israel
From €3090EUR$3,500USD£2,679GBP
- Report
- June 2024
- 200 Pages
Global
From €7020EUR$7,950USD£6,085GBP
- Report
- July 2024
- 105 Pages
Global
From €4194EUR$4,750USD£3,635GBP
- Report
- April 2023
- 147 Pages
Global
From €4370EUR$4,949USD£3,788GBP

The Hyperlipidemia Drug market is a subset of the Cardiovascular Drugs market, which focuses on the treatment of high levels of lipids in the blood. Hyperlipidemia is a condition that can lead to an increased risk of heart disease, stroke, and other cardiovascular diseases. Common treatments for hyperlipidemia include statins, fibrates, and cholesterol absorption inhibitors. Statins are the most commonly prescribed drugs for hyperlipidemia, as they are effective in reducing cholesterol levels. Fibrates are used to reduce triglyceride levels, while cholesterol absorption inhibitors reduce the absorption of cholesterol from the diet.
Some companies in the Hyperlipidemia Drug market include Pfizer, Merck, AstraZeneca, Sanofi, and Bristol-Myers Squibb. Show Less Read more